TY - JOUR
T1 - Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer
AU - Lu, Ya Ching
AU - Chang, Joseph Tung Chieh
AU - Huang, Yu Chen
AU - Huang, Chi Che
AU - Chen, Wen Ho
AU - Lee, Li Yu
AU - Huang, Bing Shen
AU - Chen, Yin Ju
AU - Li, Hsiao Fang
AU - Cheng, Ann Joy
N1 - Publisher Copyright:
© 2014 The Canadian Society of Clinical Chemists.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Objectives: The aim of this study was to determine whether the oncogenic microRNA family members miR-196a and miR-196b can be circulating biomarkers for the early detection of oral cancer. Design and methods: To determine the stability of circulating miRNA, the blood sample was aliquot and stored at different temperature conditions for analysis. To assess the diagnostic efficacy, we determined the levels of miR-196s in plasma samples, including 53 from healthy individuals, 16 from pre-cancer patients, and 90 from oral cancer patients. Results: In general, circulating miRNA was very stable when storing plasma samples at -20. °C or below. In clinical study, both circulating miR-196a and miR-196b were substantially up-regulated in patients with oral pre-cancer lesions (5.9- and 14.8-fold, respectively; P<. 0.01), as well as in oral cancer patients (9.3- and 17.0-fold, respectively; P<. 0.01). These results show prominent discrimination between normal and pre-cancer patients (AUC = 0.764 or 0.840, miR-196a or miR-196b, respectively), and between normal and cancer patients (AUC = 0.864 or 0.960, miR-196a or miR-196b, respectively). The combined determination of miR-196a and miR-196b levels produces excellent sensitivity and specificity in the diagnosis of patients with oral pre-cancer (AUC = 0.845) or oral cancer (AUC = 0.963), as well as in the prediction of potential malignancy (AUC = 0.950, sensitivity. = 91%, specificity. = 85%). Conclusion: Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
AB - Objectives: The aim of this study was to determine whether the oncogenic microRNA family members miR-196a and miR-196b can be circulating biomarkers for the early detection of oral cancer. Design and methods: To determine the stability of circulating miRNA, the blood sample was aliquot and stored at different temperature conditions for analysis. To assess the diagnostic efficacy, we determined the levels of miR-196s in plasma samples, including 53 from healthy individuals, 16 from pre-cancer patients, and 90 from oral cancer patients. Results: In general, circulating miRNA was very stable when storing plasma samples at -20. °C or below. In clinical study, both circulating miR-196a and miR-196b were substantially up-regulated in patients with oral pre-cancer lesions (5.9- and 14.8-fold, respectively; P<. 0.01), as well as in oral cancer patients (9.3- and 17.0-fold, respectively; P<. 0.01). These results show prominent discrimination between normal and pre-cancer patients (AUC = 0.764 or 0.840, miR-196a or miR-196b, respectively), and between normal and cancer patients (AUC = 0.864 or 0.960, miR-196a or miR-196b, respectively). The combined determination of miR-196a and miR-196b levels produces excellent sensitivity and specificity in the diagnosis of patients with oral pre-cancer (AUC = 0.845) or oral cancer (AUC = 0.963), as well as in the prediction of potential malignancy (AUC = 0.950, sensitivity. = 91%, specificity. = 85%). Conclusion: Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
KW - Circulating miRNA
KW - Early detection
KW - MiR-196a
KW - MiR-196b
KW - Oral cancer
UR - http://www.scopus.com/inward/record.url?scp=84921715825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921715825&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2014.11.020
DO - 10.1016/j.clinbiochem.2014.11.020
M3 - Article
C2 - 25485932
AN - SCOPUS:84921715825
SN - 0009-9120
VL - 48
SP - 115
EP - 121
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 3
ER -